TAM October/November 2026 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
October/November 2026, Volume 34, Issue 4
Overview
- CME Credit Available: 3.0 AMA PRA Category 1 Credits™
- Release Date: October 28, 2026
- Expiration Date: October 28, 2027
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which includes 3 articles covering important information on COVID-19 treatment, vaccination recommendations for people with HIV, and pharmacologic management of antiretroviral therapy for people with HIV, the learner will be able to:
- Describe current treatment recommendations for acute COVID-19 and evaluate emerging therapeutic approaches for long COVID
- Outline current vaccination recommendations for people with HIV, taking into consideration immune status, vaccine timing, and contraindications
- Describe pharmacology principles to optimize antiretroviral dosing and formulations, manage drug-drug interactions, and minimize toxic effects and resistance in people with HIV
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from October 28, 2026, to October 28, 2027. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below.
Contributors
Dr Burger reported serving as a consultant or advisor with fees paid to his institution from Merck Sharp & Dohme; and grants to his institution from Merck Sharp & Dohme, Gilead Sciences, Inc, and ViiV Healthcare. (Updated August 20, 2026)
Dr Dunlevy reported no relevant financial relationships with ineligible companies. (Updated October 28, 2026)
Dr Erdmann reported serving on the data and safety monitoring board for Pfizer, and receiving a patent for his intellectual property (IP), human neutralizing antibodies against SARS-CoV-2/COVID-19, licensed to the Plantform Corporation. (Updated October 28, 2026)
Dr Johnson reported no relevant financial relationships with ineligible companies. (Updated October 20, 2026)
Ms Opsteen reported no relevant financial relationships with ineligible companies. (Updated October 20, 2026)
Planners/Reviewers
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated October 9, 2026)
Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated October 12, 2026)
Planner/Reviewer 3 reported no relevant financial relationships with ineligible companies. (Updated October 20, 2026)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated October 0, 2026)
Dr Benson reported grants/grants pending to her institution from BioMerieux; serving on an independent data and safety monitoring committee for ViiV Healthcare, Ltd.(Updated October 12, 2026)
Dr Hirsch reported no relevant financial affiliations with ineligible companies. (Updated October 12, 2026)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Platinum Supporters
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
Additional Supporter
Hologic, Inc
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
You must be logged in to access this course.